Advertisement

Lactitol, a Potential Second Generation Disaccharide Drug for the Treatment of Portal-Systemic Encephalopathy

  • M. Bührer
  • J. Bircher

Abstract

In 1966 the first report of the beneficial effects of lactulose in the treatment of chronic portal systemic encephalopathy was published.1 In the meantime, this drug has become accepted as drug of choice for this condition,2 but also some disadvantages of lactulose — available only as syrup with a very sweet taste and contamination by other sugars — have now been recognized. Unfortunately these features may lead to aversion against the drug, to nausea related to the hyperosmolarity of the syrup and consequently to suboptimal treatment. In view of these difficulties it is surprising that no analogs with more favorable physiochemical properties have as yet been investigated.

Keywords

Hepatic Encephalopathy Sweet Taste Hepatic Coma Chronic Liver Failure Conjugate Bile Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    J. Bircher, J. Müller, P. Guggenheim, and U. P, Hämmerli, Treatment of chronic portal-systemic encephalopathy with lactulose, Lancet 1: 890 (1966).PubMedGoogle Scholar
  2. 2.
    H. O. Conn and M. M. Lieberthal,“The hepatic coma syndromes and lactulose,” The Williams and Wilkins Co., Baltimore (1979).Google Scholar
  3. 3.
    J. A. van Velthuijsen, Food additives derived from lactulose; lactitol and lactitol palmitate, J. Agricult. Food Chem. 27: 680 (1979).CrossRefGoogle Scholar
  4. 4.
    J. Bircher, M. Bührer, K. Franz, and J. A. van Velthuijsen, Erstmalige Anwendung von Lactitol in der Behandlung der portosystemischen Encephalopathie, Schweiz. Med. Wschr. 112: 1306 (1982).Google Scholar
  5. 5.
    B. G. Parsons-Smith, W. Summerskill, A. M. Dawson, and S. Sherlock, The electroencephalograph in liver disease, Lancet II: 867 (1957).CrossRefGoogle Scholar
  6. 6.
    R. Zeegen, J. E. Drinkwater, and A. M. Dawson, Methods for measuring cerebral dysfunction in patients with liver disease, Brit. Med. J. II: 633 (1970).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • M. Bührer
    • 1
  • J. Bircher
    • 1
  1. 1.Department of Clinical PharmacologyUniversity of BerneBerneSwitzerland

Personalised recommendations